Skip to main content
OpenTrials
Completed

NCT Number: NCT03268902

Early Life Interventions for Childhood Growth and Development In Tanzania

This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.

Completed

Looking for future studies?

Notify Me

Key information

Age range

0 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Haydom Lutheran Hospital

Haydom, Manyara Region, Tanzania

About this study

Children living in rural sub-Saharan Africa experience massive challenges to child thriving, with poor linear growth and delays in child development. In a cohort of 211 children living in the rural Haydom area of Tanzania (participating in the Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development "MAL-ED" Study), 70.6% had stunted growth at 18 months. This rate of moderate and severe stunting (length-for-age z-score [HAZ] <-2 standard deviations) was the highest of the 8 study sites in MAL-ED.

This enormous deficit is likely associated with high rates of enteric infections with Campylobacter, E. coli pathotypes, Cryptosporidium, and Giardia, organisms susceptible to azithromycin and/or nitazoxanide. Infections such as these occur frequently in developing areas and are often associated with environmental enteropathy, including ongoing enteric inflammation and loss of enterocyte integrity, leading to possible bacterial translocation and poorer absorption of ingested nutrients. The consequences of these infections, enteric dysfunction and poor nutrient absorption frequently include growth stunting, learning delays, and an overall loss of human capital.

Emerging evidence suggests a potential role for the tryptophan-niacin pathway (including the end-product nicotinamide, an isoform of vitamin B3) in decreasing mucosal inflammation and affecting enteral microbiota. At the Tanzania site of MAL-ED, serum levels of tryptophan were related to subsequent linear growth, further suggesting importance of the tryptophan-niacin pathway. What is not clear is whether early childhood growth and development could be improved by targeting enteric infection and the tryptophan-niacin pathway by 1) delivering antibiotics against specific bacteria and/or 2) providing vitamin B3 as nicotinamide/niacinamide.

The main analysis will be intention-to-treat but a secondary analysis will be per protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Maternal age ≥18
  • Infant ≤ 14 days

Exclusion criteria

  • Maternal inability to adhere to protocol
  • Multiple gestation
  • Severe illness (significant birth defect, hospitalization, severe neonatal illness)
  • Birth weight <1500 g
  • Lack of breastfeeding at enrollment (and lack of intention to continue breastfeeding at time of enrollment).

Treatment and study plan

Azithromycin Oral Liquid Product

Drug

Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months

Other names: Throza DPS

Nitazoxanide Oral Suspension

Drug

Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months

Other names: Alinia

Nicotinamide

Dietary Supplement

Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.

Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age

Other names: Vitamin B3

Placebos

Drug

Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.

Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.

Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age

Primary outcomes

  1. Height-for-age z-score (HAZ) at 18 months

    Time frame: 18 months

Secondary outcomes

  1. Weight-for-age z-score (WAZ) at 18 months

    Time frame: 18 months

  2. Head circumference-for-age z-score (HCAZ) at 18 months

    Time frame: 18 months

  3. Stunting

    Time frame: 18 months

    HAZ <-2

  4. All cause mortality

    Time frame: 0-18 months

  5. Hospitalization

    Time frame: 0-18 months

  6. Childhood illness

    Time frame: 0-18 months

    Incidence of diarrhea, lower respiratory infection and febrile illness

  7. Anemia

    Time frame: 12 and 18 months

    Moderate to severe anemia by WHO definition for age and altitude

  8. Enteropathogen burden

    Time frame: 6, 6.5, 12, 12.5, 18 months

  9. Microbiota composition

    Time frame: 6, 6.5, 12, 18 months

    Composition of intestinal microbiome

  10. Stool myeloperoxidase concentration

    Time frame: 6, 12, 18 months

    Stool myeloperoxidase ELISA

  11. C-reactive protein concentration in serum

    Time frame: 12 and 18 months

    High-sensitivity CRP concentration

  12. Insulin-like growth factor 1 concentration in serum

    Time frame: 12 and 18 months

  13. Collagen X concentration in serum

    Time frame: 12 and 18 months

  14. Tryptophan-kynurenine ratio

    Time frame: 12 and 18 months

    Ratio of tryptophan concentration to kynurenine concentration in metabolomic testing

  15. Niacin and nicotinamide metabolite concentration

    Time frame: 6, 12, 18 months

    Concentration of downstream metabolites of niacin and nicotinamide as tested by metabolomic analysis

  16. Small intestinal bacterial overgrowth

    Time frame: 6, 12 and 18 months

    Prevalence of SIBO as tested via exhaled hydrogen

  17. Malawi Developmental Assessment Tool score

    Time frame: 18 months

    The MDAT is a measure of child cognitive development

Sponsors and collaborators

Lead sponsor

Haydom Lutheran Hospital

Other

Collaborators

  • Bill and Melinda Gates Foundation
  • University of Virginia

Registry information

Acronym: ELICIT

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Aug 31, 2017
Registry last updated
May 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.